to Rule 416 under the Securities Act, the shares of common stock registered hereby also
include an indeterminate number of additional shares of common stock as may from time
accordance with Rule 457(g) under the Securities Act, because the shares of common stock
Series B Preferred, with a stated value of $1,000 and convertible into shares of our common stock at the public offering price
12, 2017, the last reported sale price for our common stock on NASDAQ was $0.39 per share.
offering price per Class A Unit will be determined between us and the underwriter based on the closing price of our common stock
aggregate total of 7,692,308 shares of Common Stock and the Warrants included in the Class B Units will be exercisable for an
have elected to comply with certain reduced public company reporting requirements for future filings.Investing
have granted a 45-day option to the underwriter to purchase a maximum of 2,307,692 additional shares of common stock (15% of the
included as part of the Class B Units sold in this offering) and warrants to purchase a maximum of 2,307,692 shares of common
724,200 shares of common stock of the Company issued in March 2017
exercise price equal to 125% of the public offering price of the Class A Units per share of common stock.
of our Series B Preferred, with a stated value of $1,000 and convertible into shares of our common stock, at the public offering
share of common stock, will be exercisable upon issuance, and will expire five years from the date of issuance.Series
B ConvertiblePreferred Stock:The Series B Preferred will be convertible into shares of our common stock (subject to adjustment as provided in the related certificate
of designation of preferences, rights and limitations) at any time at the option of the holder, at the public offering price of
2,307,692 shares of common stock (15% of the warrants included as part of the Units sold
the total number of shares of our common stock outstanding immediately following the
estimate that the net proceeds from our sale of shares of our common stock in this offering will be approximately $5.4 million,
weighted average exercise price of $1.39 per share.•7,692,308 shares of our common stock issuable upon exercise of the warrants to be issued in this offering;•7,692,308
shares of our common stock issuable upon conversion of the Series B Preferred to be issued in this offering; and•769,231
shares of our common stock issuable by the Company upon exercise of the underwriter’s warrants (5% of the shares of
the warrants).•The number of shares of our common stock outstanding after this offering will fluctuate depending on how many Class B Units
expected for the fiscal year 2017.Summary of Statement of Operations DataNine Months EndedSeptember 30,Fiscal Year EndedDecember 31,2017201620162015Total revenue$2,540,942$2,307,708$2,960,912$2,115,050Cost of sales$846,487$713,576$1,083,087$950,792Gross profit$1,694,455$1,594,132$1,877,825$1,164,258Net loss$(3,193,571)$(2,207,707)$(3,303,538)$(9,311,913)Basic and diluted net loss per share$(0.39)$(.41)$(.61)$(1.81)Weighted average basic and diluted shares
employees; and•a pro forma, as adjusted basis, giving effect to (i) the sale by us of 7,692,308 Class A Units, at the assumed public offering
adversely affect the Company’s business.We may require additional capital in the future to develop new
The estimated research and development expense for the year ending December 31, 2017 is $1,250,000.Even if completed, we do not know if these trials will produce
may be unable to develop marketable products.Modifications to our devices may require additional FDA approval
financial position, cash flows and results of operations.Failure to obtain medical reimbursement for our products under
stock price.The preparation of financial statements in conformity with U.S. GAAP requires our management to make estimates, assumptions and
accounts, stock-based compensation expense and income taxes.As an emerging growth company within the meaning of the Securities
common stock less attractive to investors.We are an emerging growth company within the meaning of the rules
requirement, we would expect our common stock to be traded in the over-the-counter market, which could adversely affect the liquidity
or events that support this determination:The Company’s current working capital position.The Company is working diligently to raise additional working
business, operating results and financial condition.26The Series B Preferred Stock will be an unlisted security and as
to receive dividends, but rather merely represent the right to acquire shares of common stock at a fixed price for a limited period
by our stockholders of a substantial number of shares of our common stock in the public market could occur in the future.
sales, or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could
result in a dilution of your voting power and an increase in the number of shares of common stock eligible for future resale in
the public market, which may negatively impact the trading price of our shares of common stock.The
of December 12, 2017, we had outstanding warrants to purchase up to 1,490,570 shares of our common stock at a weighted exercise
are exercised (including with respect to the warrants and any Series B Preferred issued in this offering), additional shares of
public offering price per share of common stock in this offering will be substantially higher than the net tangible book value
in a manner that does not produce income or that loses value.Sales of a substantial number of shares of our common stock
of a substantial number of shares of our common stock in the public market or otherwise following this offering, or the
perception that such sales could occur, could adversely affect the market price of our common stock.
as amended, permits the issuance of up to approximately 482,387,140 additional shares of common stock after the completion of
ownership held by the investors who purchase shares of our common stock in this offering.We and our officers, directors
high and low market prices per share of our common stock on The
warrants to be issued in this offering, (v) shares of our common stock issuable upon conversion of the Series B Preferred to be
the extent we sell any Class B Units in this offering, the same aggregate number of common stock equivalents resulting from this
2017, each after giving effect to the receipt of the net proceeds from our sale in this offering of shares of common stock at
public offering price per share of common stock$0.39Historical
warrants to be issued in this offering, (v) shares of our common stock issuable by the Company upon exercise of the underwriter’s
warrants to be issued in this offering, (v) shares of our common stock issuable by the Company upon exercise of the underwriter’s
warrants (5% of the shares of common stock sold in this offering, including shares issuable upon conversion of the Series B Preferred
number of shares of our common stock outstanding after this offering will fluctuate depending on how many Class B Units are sold
number of shares of our common stock outstanding after this offering will fluctuate depending on how many Class B Units are sold
number of shares of our common stock outstanding after this offering will fluctuate depending on how many Class B Units are sold
PulmoHealth, BreathScan®DKA and PIFA PLUSS®Infectious Disease point-of-care tests; and•to expand the use of its clinical laboratory products, the Company
production team significantly increased direct labor costs.Cost of sales for the nine months ended September 30, 2017 totaled
EndedDecember 31, 2015PercentChangeProfessional Services$885,746$1,233,136(28)%Stock Market & Investor Relations441,453572,161(23)%Travel Costs118,980268,201(56)%Total$1,446,179$2,073,488(30)%Professional services included significant decreases in employment
December 31, 2016.44The Company recognized cost savings in all of its stock market and
Rapid Assay product.Sales and Marketing ExpensesSales and marketing expenses in the year ended December 31, 2016
sales and marketing expenses for the years ended December 31, 2016
clinical effectiveness of the products.Professional service costs declined 77% during the year ended
U.S.Federal tax effect(6.0)%(6.0)%Benefit from sale of New Jersey NOL0.0%(2.9)%Change in Valuation Allowance41.0%41.0%Net0.0%(2.9)%Liquidity and Capital ResourcesFor the nine months ended September 30, 2017 and 2016, the Company
intangibles and stock-based compensation.The Company’s financial position, results of operations and
Company (including any such issuance of shares of capital stock of
Market Value of such share of the Company’s Common Stock on
of 295,107 shares of Restricted stock.As of December 4, 2017, under the Plan, the Company has issued
pursuant to a resolution approved by the majority of the Board of Directors.Dividend RightsThe holders of outstanding shares of common stock are entitled to
statement registering the issuance of the shares of common stock underlying the warrants under the Securities Act is effective
If a registration statement registering the issuance of the shares of common stock underlying the warrants
in which case the holder would receive upon such exercise the net number of shares of common stock determined according to the
Class B Units sold in this offering) and/or warrants to purchase a maximum of 2,307,692 shares of common stock (15% of the warrants
or part of this option, it will purchase such common stock covered by the option at the public offering price per Class A Unit,
securities.An offer to the public of common stock has not been made, and may
that no such offer of common stock shall result in a requirement
have filed with the SEC a registration statement on Form S-1 under the Securities Act with respect to the shares of common stock,
services are to be received or the vesting period.The Company accounts for stock-based compensation awards to
options were greater than the market price of the common stock.F-12AKERS BIOSCIENCES, INC.
number of shares of common stock.The Company did not issue any options or warrants under the above
Company’s common stock on the grant date.On June 8, 2016, the Company issued 27,500 restricted common shares
number of shares of common stock.On December 30, 2015, the Company approved the issuance of 30,000
stock price of $1.90 and $1.21 for our common shares on December
Company.A restricted stock award is an award of common shares that are
Company.A restricted stock award is an award of common shares that are
price of the Company’s common stock on the grant date.On January 9, 2015, the Company issued 190,000 common shares to
Company’s financial statements for the year ended December
Company’s financial statements for the year ended December
collectable.Product revenue — related party for the year ended December
collectable.Product revenue — related party for the year ended December
offering.During the twelve-month period ended December 31, 2016, the Company